Insider Trading Alert - DVA, TMH, B, AFOP And WST Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Nov. 8, 2013, 143 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $296.78 to $400,200,000.00.

Highlighted Stocks Traded by Insiders:

DaVita HealthCare Partners (DVA) - FREE Research Report

Berkshire Hathaway Inc who is 10% Owner at DaVita HealthCare Partners bought 3.7 million shares at $55.14 on Nov. 8, 2013. Following this transaction, the 10% Owner owned 35.1 million shares meaning that the stake was reduced by 11.77% with the 3.7 million share transaction.

Weschler, R. Ted who is Member of 10% owner group at DaVita HealthCare Partners bought 3.7 million shares at $55.14 on Nov. 8, 2013. Following this transaction, the Member of 10% owner group owned 35.1 million shares meaning that the stake was reduced by 11.77% with the 3.7 million share transaction.

The shares most recently traded at $56.88, up $1.74, or 3.05% since the insider transaction.

The average volume for DaVita HealthCare Partners has been 1.4 million shares per day over the past 30 days. Shares are up 0.9% year to date as of the close of trading on Friday.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. The company has a P/E ratio of 20.5. Currently there are 7 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DVA - FREE

TheStreet Quant Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full DaVita HealthCare Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Team Health Holdings (TMH) - FREE Research Report

Davenport Glenn A. who is Director at Team Health Holdings sold 15,000 shares at $44.07 on Nov. 8, 2013. Following this transaction, the Director owned 22,522 shares meaning that the stake was reduced by 39.98% with the 15,000 share transaction.

The shares most recently traded at $44.74, up $0.67, or 1.5% since the insider transaction.

The average volume for Team Health Holdings has been 528,100 shares per day over the past 30 days. Team Health Holdings has a market cap of $3.0 billion and is part of the services sector and diversified services industry. Shares are up 51.65% year to date as of the close of trading on Friday.

Team Health Holdings, Inc. provides outsourced healthcare professional staffing and administrative services to hospitals and other healthcare providers in the United States. The company has a P/E ratio of 38.3. Currently there are 7 analysts that rate Team Health Holdings a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TMH - FREE

TheStreet Quant Ratings rates Team Health Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, good cash flow from operations, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Team Health Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Barnes Group (B) - FREE Research Report

Barnes Thomas O who is Director at Barnes Group sold 7,952 shares at $36.59 on Nov. 8, 2013. Following this transaction, the Director owned 467,902 shares meaning that the stake was reduced by 1.67% with the 7,952 share transaction.

Mangum Mylle H who is Director at Barnes Group sold 4,500 shares at $36.00 on Nov. 8, 2013. Following this transaction, the Director owned 21,877 shares meaning that the stake was reduced by 17.06% with the 4,500 share transaction.

The shares most recently traded at $36.55, up $0.55, or 1.49% since the insider transaction.

The average volume for Barnes Group has been 349,300 shares per day over the past 30 days. Barnes Group has a market cap of $1.9 billion and is part of the industrial goods sector and industrial industry. Shares are up 60.2% year to date as of the close of trading on Friday.

Barnes Group Inc. operates as an aerospace and industrial manufacturing and service provider serving a range of end markets and customers worldwide. The company operates in three segments: Aerospace, Industrial, and Distribution. The stock currently has a dividend yield of 1.22%. The company has a P/E ratio of 21.8. Currently there are 3 analysts that rate Barnes Group a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on B - FREE

TheStreet Quant Ratings rates Barnes Group as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Barnes Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Alliance Fiber Optic Products (AFOP) - FREE Research Report

Sun Ray Rei-Kung who is Director at Alliance Fiber Optic Products sold 1,000 shares at $15.68 on Nov. 8, 2013. Following this transaction, the Director owned 6,500 shares meaning that the stake was reduced by 13.33% with the 1,000 share transaction.

The shares most recently traded at $16.03, up $0.35, or 2.21% since the insider transaction. Historical insider transactions for Alliance Fiber Optic Products go as follows:

  • 4-Week # shares sold: 6,500
  • 12-Week # shares sold: 548,500
  • 24-Week # shares sold: 791,500

The average volume for Alliance Fiber Optic Products has been 1.1 million shares per day over the past 30 days. Alliance Fiber Optic Products has a market cap of $274.4 million and is part of the technology sector and electronics industry. Shares are up 151.91% year to date as of the close of trading on Friday.

Alliance Fiber Optic Products, Inc. designs, manufactures, and markets various fiber optic components and integrated modules for communications equipment manufacturers and service providers in North America, Europe, and Asia. The stock currently has a dividend yield of 0.83%. The company has a P/E ratio of 15.6. Currently there are no analysts that rate Alliance Fiber Optic Products a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AFOP - FREE

TheStreet Quant Ratings rates Alliance Fiber Optic Products as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Alliance Fiber Optic Products Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

West Pharmaceutical Services (WST) - FREE Research Report

Anderson Michael A who is Vice President & Treasurer at West Pharmaceutical Services sold 9,200 shares at $46.80 on Nov. 8, 2013. Following this transaction, the Vice President & Treasurer owned 73,406 shares meaning that the stake was reduced by 11.14% with the 9,200 share transaction.

Malone Daniel who is Vice President & Controller at West Pharmaceutical Services sold 3,718 shares at $46.57 on Nov. 8, 2013. Following this transaction, the Vice President & Controller owned 8 shares meaning that the stake was reduced by 99.79% with the 3,718 share transaction.

The shares most recently traded at $46.71, up $0.14, or 0.3% since the insider transaction. Historical insider transactions for West Pharmaceutical Services go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 17,883
  • 24-Week # shares sold: 20,883

The average volume for West Pharmaceutical Services has been 251,200 shares per day over the past 30 days. West Pharmaceutical Services has a market cap of $3.2 billion and is part of the health care sector and health services industry. Shares are up 67.67% year to date as of the close of trading on Friday.

West Pharmaceutical Services, Inc. manufactures and sells components and systems for injectable drug delivery and plastic packaging, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The stock currently has a dividend yield of 0.87%. The company has a P/E ratio of 29.6. Currently there is 1 analyst that rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WST - FREE

TheStreet Quant Ratings rates West Pharmaceutical Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full West Pharmaceutical Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists